Discover
QNRX
Quoin Pharmaceuticals, Ltd.
5.09
1 x 5.00
2 x 5.28
bid
ask
-
0.96
15.87%
1 @ 04:00 PM
4.94 -0.15 (2.95%)
| Ytd | -64.73% | |
| 1y | -30.27% |
4.67
day range
5.28
3.25
52 week range
22.30
| Open | 5.18 | Prev Close | 6.05 | Low | 4.67 | High | 5.28 | Mkt Cap | 10.22M |
| Vol | 64.68K | Avg Vol | 242.14K | EPS | -29.56 | P/E | -0.17 | Forward P/E | -0.43 |
| Beta | 1.89 | Short Ratio | 0.20 | Inst. Own | 5.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.53 | 200-d Avg | 8.41 | 1yr Est | 4.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.44 | -0.47 | -0.03 | -6.82% |
| 2024-08-08 | 2024-06 | -0.75 | -0.39 | 0.36 | 48.00% |
| 2024-05-09 | 2024-03 | 0 | -1.11 | N/A | N/A |
| 2024-03-13 | 2023-12 | -2.37 | -2.08 | 0.29 | 12.24% |
| 2023-11-08 | 2023-09 | -2.4 | -1.95 | 0.45 | 18.75% |
| 2023-08-02 | 2023-06 | 0 | -2.13 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-03-15 | Maxim Group | Upgrade | Buy | Buy |
Profile
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-03 | CARTER DENISE P | Chief Operating Officer | 47.09K | Purchase |
| 2024-09-09 | DUNN GORDON | Chief Financial Officer | 28.86K | Purchase |
| 2024-09-03 | MYERS MICHAEL | Chief Executive Officer | 47.25K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Renaissance Technologies, LLC | 38.69K | 20.20K | 0.77% |
| 2024-09-29 | Two Sigma Securities, LLC | 31.85K | 16.63K | 0.63% |
| 2024-09-29 | Raymond James Financial Services Advisors, Inc. | 25.12K | 13.11K | 0.50% |
| 2024-09-29 | Virtu Financial LLC | 25.17K | 13.14K | 0.50% |
| 2024-09-29 | UBS Group AG | 22.82K | 11.91K | 0.45% |
| 2024-09-29 | Rhumbline Advisers | 20.79K | 10.85K | 0.41% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-04-29 | Fidelity NASDAQ Composite Index Fund | 95.00 | 49.00 | 0.00% |
Split
| Split | Date |
|---|---|
| 1 : 35 | 2025-04-09 |
| 1 : 12 | 2023-07-18 |
| 1 : 12 | 2023-07-17 |
| 2 : 25 | 2022-08-01 |
| 1 : 4 | 2021-09-24 |
| 1 : 5 | 2019-10-23 |